Company intelligence / Profile preview

Revivicor

Blacksburg, Virginia, United States

Ownership: Private
Development stage: Other

Overview

Revivicor achieved several firsts: gene-edited pig kidney and heart transplants performed in humans (including longest-to-date survival of a porcine xenotransplant product) but products are not yet commercially approved; FDA approved use of GalSafe™ pigs for human food and medical products

Therapeutic areas: NephrologyCardiovascular
Modalities: Gene-edited organ transplant (Biologic)Xenotransplantation
Industry: Biotech

Partnerships

Roslin Institute (historical)NYU Langone Health (clinical collaborations on xenotransplantation)

Beyond the preview

Go deeper on Revivicor.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Revivicor.

Explore the full profile